The introduction of generative artificial intelligence (AI) into the life sciences manufacturing sector heralds a new era of innovation and efficiency. With the life sciences field continuously pushing for faster product launches, increased production capacity, enhanced supply chain security, and
Phlow Corp., a company dedicated to advancing the Richmond region into a hub for pharmaceutical manufacturing, is making significant strides as it raises $25 million from investors. Following the initiation of its medicine ingredients manufacturing operations in Petersburg last year, this
In a recent significant development set to change the healthcare landscape, Germfree and Orgenesis Inc. have joined forces. This strategic partnership establishes a noble ambition: to revolutionize the production of much-needed cell and gene therapies. The aim is clear—to enhance the availability
In a bold move to expand its immunology portfolio, Johnson & Johnson has announced the acquisition of Proteologix, Inc. for an $850 million upfront payment, with additional milestone payments on the horizon. This strategic purchase positions Johnson & Johnson at the forefront of biotechnological
As we progress into the 2020s, the pharmaceutical industry is steered toward an era of both exciting potential and challenges. The year 2024 is poised to be pivotal, influenced by a complex mix of factors including rigorous regulation, technological advancements, demand for sustainability, and the
The utilization of artificial intelligence (AI) is transforming the pharmaceutical industry, infusing manufacturing practices with unprecedented efficiency and innovation. However, this surge of technological advancement beckons a new era of regulation, presenting unique challenges for
